Preparing Your Business for 2026: Conduct a Regulatory Health Check with Stone Okamont
As we close the first quarter of 2026, international executives operating in Brazil face a critical timeline. If your goal is to end the year with record-breaking revenue and new products on the shelves, the question isn't just "how much do I want to sell?" but rather: "Is my company resilient enough for Brazil’s 2026 regulatory evolution?"
In the Brazilian landscape, neglecting a bureaucratic detail in March can lead to a fatal operational shutdown by October. Just as a routine physical prepares your body for daily stress, your company requires an Annual Regulatory Health Check to prevent disruptions during peak market moments.
The 3 Vital Signs of Your Business’s Regulatory Health
In the sectors governed by ANVISA (Health) and MAPA (Agriculture), your company’s "health" is measured by the accuracy and validity of your licenses. During our check-up, we focus on three fundamental pillars:
-
01
01. AFE (Operating Authorizations) & Licenses
Is your AFE (Operating Authorization) up to date with ANVISA? Changes in company size, address, or the addition of new product categories require immediate updates. In Brazil’s current 2026 climate, operating with outdated information is a high-risk move that can lead to heavy fines or immediate suspension of activities.
-
02
02. GMP Certification (Good Manufacturing Practices)
Whether it’s your facility or a contract manufacturer, GMP (BPF) certification must be valid. Without a current GMP certificate, you cannot register new products. In critical scenarios, ANVISA may even suspend the sale of existing products if the manufacturing site's certification expires.
-
03
03. Traceability and Labeling
Transparency and supply chain control standards have become increasingly stringent in 2026. Labeling inconsistencies or traceability gaps can trigger rapid recalls and notifications, directly impacting your brand’s reputation and bottom line.
The Risks of Handling Regulatory Compliance Alone
Many managers try to resolve regulatory issues internally with the goal of reducing costs. However, the risk of handling regulatory compliance alone often results in massive time losses. In the regulatory environments of ANVISA and MAPA, the primary risk is not the immediate cost, but lost time. Market time is an asset that cannot be recovered, and these delays can lead to failed product launches and open windows for competitors to seize your space.
An incomplete or inadequate process usually results in Technical Requirements (Exigências), which are formal requests for corrections that can halt an analysis and delay a launch by six months or more. In competitive segments like supplements and cosmetics, this interval is enough for competitors to occupy the shelf space that should have been yours.
The diagnosis is objective: Prevention costs less than correction. A well-structured protocol from the beginning reduces the risk of requirements, avoids rework, optimizes timelines, and strengthens your company's credibility with regulatory bodies.
Is Your Company Ready for 2026?
At Stone Okamont, we don’t just fill out forms. We perform a technical and strategic analysis to identify risks and fix vulnerabilities. Our approach focuses on predictability and long-term performance, ensuring your company is ready to grow with regulatory safety in 2026 and beyond.
Our goal is to keep your business protected against the unexpected, so you can focus your efforts on what really matters: managing, growing, and expanding your brand.
Don’t wait to find out if your company is ready. Schedule your regulatory diagnosis with Stone Okamont today.